RLIM

Across TCGA pan-cancer cohorts, RLIM mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RLIM data layer compared with 28 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RLIM mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RLIM expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where RLIM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.252	0.778	.002	28	view →
LUAD	DFS	Median	All	0.792	0.448	.001	17	view →
CCRCC	DFS	Median	II,III,IV	1.000	0.835	.007	12	view →
LSCC	OS	Quartile	II,III,IV	0.839	1.000	.036	3	view →
GBM	OS	Quartile	All	0.519	0.312	.048	2	view →
UCEC	DFS	Median	All	1.000	0.932	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RLIM–PDAC (OS)

Open the PDAC breakdown →